Loading...

Major Indexes

Operating Data

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals Inc. (ICPT)

$45.09
1.23 (+2.80%)

Operating Data

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 1.621.742.7824.95130.96179.81252.00825.852,706.478,869.6429,067.59
Revenue (%)
EBITDA -66.07-279.42-218.44-393.08-326.17-279.33-306.30-35,476.95-116,265.06-381,023.87-1,248,691.42
EBITDA (%)
EBIT -67.79-283.23-226.43-402.54-335.61-285.48-312.43-36,259.19-118,828.63-389,425.19-1,276,224.24
EBIT (%)
Depreciation 1.723.817.999.459.446.156.12782.242,563.578,401.3327,532.82
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)